title: The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis.
abstract: A new orally active drug, laquinimod (ABR-215062), was shown to completely inhibit the development of murine acute experimental autoimmune encephalomyelitis (EAE). Furthermore, leukocyte infiltration into the central nervous system (CNS) was abolished in the laquinimod-treated animals. By direct comparison based on dose and total exposure, laquinimod was approximately 20 times more potent than the immunomodulator roquinimex. Laquinimod also had clear therapeutic effect when given after clinical onset in a chronic relapsing EAE model. It therefore represents a new orally active immunoregulatory drug without general immunosuppressive properties for the treatment of the autoimmune disease multiple sclerosis.
authors.affiliation: Active Biotech Research AB, Box 724, S-220 07, Lund, Sweden.
authors.forename: Charlott
authors.initials: C
authors.lastname: Brunmark
authors.forename: Anna
authors.initials: A
authors.lastname: Runström
authors.forename: Lennart
authors.initials: L
authors.lastname: Ohlsson
authors.forename: Birgitta
authors.initials: B
authors.lastname: Sparre
authors.forename: Thomas
authors.initials: T
authors.lastname: Brodin
authors.forename: Mikael
authors.initials: M
authors.lastname: Aström
authors.forename: Gunnar
authors.initials: G
authors.lastname: Hedlund
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001402:B-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D002478:Cells, Cultured; D002490:Central Nervous System / Q000187:drug effects* / Q000276:immunology / Q000503:physiopathology; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000276:immunology; D003907:Dexamethasone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control*; D005260:Female; D006912:Hydroxyquinolines / Q000494:pharmacology*; D007165:Immunosuppression Therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D015213:Neuroimmunomodulation / Q000187:drug effects* / Q000276:immunology; D015363:Quinolones; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000893:Anti-Inflammatory Agents; D006912:Hydroxyquinolines; D015363:Quinolones; C045282:roquinimex; D003907:Dexamethasone; C476223:laquinimod